论文信息 - VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC - 字舞流文

VP7-2021: KEYNOTE-522: Phase III study of neoadjuvant pembrolizumab + chemotherapy vs. placebo + chemotherapy, followed by adjuvant pembrolizumab vs. placebo for early-stage TNBC

P. Fasching | L. Pusztai | C. Denkert | V. Karantza | H. McArthur | N. Harbeck | M. Untch | S. Kümmel | Masato Takahashi | Young-Ae Park | J. O’Shaughnessy | P. Schmid | K. Tryfonidis | R. Dent | G. Aktan | R. Hui | J. Cortés | Fatima Cardoso | Y. Ding | J. Bergh | M. Takahashi | J. Cortes